Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NewBridge Signs License, Supply Agreement With Axcan
NewBridge has entered into a license and supply agreement with Axcan for Pylera, a patented 3-in-1 capsule therapy for the eradication of Helicobacter pylori. Each Pylera capsule contains
NewBridge has entered into a license and supply agreement with Axcan for Pylera, a patented 3-in-1 capsule therapy for the eradication of Helicobacter pylori. Each Pylera capsule contains
Profectus BioSciences has closed on a $5 million Series C venture financing. Current investor, Cross Atlantic Capital Partners led the round, which brings the total venture investment in
Bayer Technology Services has developed a new process for the purification of acetonitrile (ACN). The four-step process now enables ACN feed stock to be purified on the ton
Affymetrix, a developer of products that accelerate genetic research, has posted its operating results that revealed a negative impact for the second quarter of 2009. The company’s total
RTI Biologics has signed an expanded agreement with Davol, a subsidiary of CR Bard. Under the agreement, RTI will supply Tutoplast for exclusive worldwide distribution by Davol for
Sinovac has initiated dosing in its clinical trial of various Panflu vaccine candidates for pandemic influenza A (H1N1). Reportedly, three types of vaccines, including split viron vaccine, split
Conceptus has reported financial results for the three and six months ended June 30, 2009. Net sales for the second quarter of 2009 were $33 million, an increase
Human Genome (HGSI) has received second purchase order from the US government as an additional 45,000 doses of raxibacumab (ABthrax), for the Strategic National Stockpile, to be delivered
Takeda Global Research & Development Center has received notification from the FDA that it has extended the review of the New Drug Application (NDA) for the fixed-dose combination
GlaxoSmithKline (GSK) has completed its acquisition of Stiefel. The company has acquired the total share capital of Stiefel for a cash consideration of $2.9 billion. Under the terms